课题基金 / 基金详情

High-throughput screening to identify modulators of PKD2 function

High-throughput screening to identify modulators of PKD2 function
高通量筛选鉴定 PKD2 功能调节剂
批准号：
10255323
负责人：
Mark Henderson
金额：
$11.24万
依托单位：
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/10255323
关键词：
Autosomal Dominant Polycystic KidneyBiological AssayBiologyCationsCell membraneCellsCollaborationsComplexDiseaseExtramural ActivitiesGoalsInformaticsIntegral Membrane ProteinModelingMutationPharmaceutical ChemistryPhenotypeProcessProprotein Convertase 1ResearchResearch PersonnelSynthesis ChemistryTranslationsUnited States National Institutes of HealthValidationWorkassay developmentbasedesigndisease-causing mutationdrug developmentdrug discoveryhigh throughput screeninglead optimizationnew technologynovelpolycystic kidney disease 1 proteinscreeningsmall moleculesmall molecule therapeuticstherapeutic developmenttool

项目摘要

项目成果

Mark Henderson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in transmembrane proteins PKD1 (PC1) or PKD2 (PC2). PC1 and PC2 subunits form a cation channel at the plasma membrane, and function can be disrupted by disease-causing mutations During this period, the team worked to design and implement a high-throughput screening amenable assay capable of identifying small molecule activators of the PC1/PC2 heteromeric complex. A novel cell-based assay of PC1/PC2 activity was developed by the Delling lab.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Novel Cell-Based Assay to Identify Small Molecules for Galactocerebrosidase (GALC)
Identifying small molecules with selective toxicity towards muscle invasive prostate cancer cells
Evaluation of CD206 agonists in diabetic retinopathy
Identification of small molecules that improve trafficking of NLGN4X/Y for autism
海外基金